Insmed reports third quarter 2022 financial results and provides business update

—arikayce® (amikacin liposome inhalation suspension) achieves 45% year over year growth for the third quarter of 2022 with total revenue of $67.7 million, marking the strongest quarter since launch — —clinical programs progressing on track; company expects to complete enrollment in phase 3 aspen trial of brensocatib in first quarter of 2023 and share topline data in second quarter of 2024— —recent strategic financings increase cash and cash equivalents and marketable securities to approximately $1.3 billion to support key upcoming milestones across four pillars— bridgewater, n.j. , oct. 27, 2022 /prnewswire/ --  insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended september 30, 2022 and provided a business update.
INSM Ratings Summary
INSM Quant Ranking